OncoGenex Pharmaceuticals (OGXI +2.6%) offers 5,559,866 Series A units and 1,340,538 Series B units for public sale. Each Series A unit consist of one share of common stock plus one warrant to purchase 1/2 share of common at $4.00 per share for a five-year term. The warrants are immediately exercisable.
The Series B units will be offered and sold to those Series A buyers whose purchases would increase their stake in the company to greater than 9.99%. Each Series B unit consists of one pre-funded warrant to purchase one share of common stock and one warrant to purchase 1/2 share of common stock at $4.00 for a five-year term.
Gross proceeds will be ~$24M.